SCHEMBL6154325

SCHEMBL6154325

Clc1cc(N(Cc2ccccc2)c2nnc(-c3cccc(Oc4ccccc4)c3)s2)ccc1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.38
ROCK1 Q13464 1/20 0.38
HDAC1 Q13547 8/20 0.36
HDAC2 Q92769 8/20 0.36
HDAC8 Q9BY41 4/20 0.36
HDAC6 Q9UBN7 4/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PGR P06401 2/20 0.35
GAA P10253 3/20 0.35
NR3C1 P04150 1/20 0.34
PTGES O14684 1/20 0.34
ALOX5 P09917 1/20 0.34
S1PR1 P21453 1/20 0.34
S1PR3 Q99500 1/20 0.34
MGAM O43451 1/20 0.34
SI P14410 1/20 0.34
MGAM2 Q2M2H8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6678797 0.81 GCGR (0.35) ROCK2ROCK1HDAC1HDAC2HDAC8
SCHEMBL6678801 0.80 HSD17B10 (0.35) ROCK2ROCK1HDAC1HDAC2HDAC8
SCHEMBL6154252 0.79 GCGR (0.39) ROCK2ROCK1HDAC1HDAC2HDAC8
SCHEMBL6155070 0.78 PTPN5 (0.45) ROCK2ROCK1NPC1LMNAHPGD
SCHEMBL6154034 0.78 KMO (0.47) ROCK2ROCK1HDAC1HDAC2HDAC8
SCHEMBL4955542 0.75 KMO (0.38) HDAC1HDAC2HDAC8HDAC6NPC1
SCHEMBL6153971 0.74 S1PR1 (0.40) NPC1LMNAHPGDHSD17B10GAA
SCHEMBL4959788 0.74 PTPN1 (0.38) HDAC1HDAC2HDAC8HDAC6NPC1
SCHEMBL4956127 0.74 KMO (0.39) ROCK2ROCK1HDAC1HDAC2HDAC8
SCHEMBL4956121 0.74 KMO (0.39) ROCK2ROCK1HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2005-03-24 US claimed
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2005-03-24 US disclosed
EP-1446110-A2 ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES Structural Bioinformatics Inc. (US) 2004-08-18 EP disclosed
WO-2003032916-A2 ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES STRUCTURAL BIOINFORMATICS INC. (US) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases PTPRS, PTPRJ, PTPRCAP ROCK2 3224/4885ROCK1 3290/4885HDAC1 1404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.